Outlook Therapeutics
OTLK
65 hedge funds and large institutions have $62.7M invested in Outlook Therapeutics in 2024 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 24 increasing their positions, 12 reducing their positions, and 7 closing their positions.
1,314% more call options, than puts
Call options by funds: $99K | Put options by funds: $7K
114% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 7
100% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 12
35% more capital inflows, than outflows
Capital inflows: $16.7M | Capital outflows: $12.3M
14% more funds holding
Funds holding: 57 → 65 (+8)
21.81% less ownership
Funds ownership: 58.1% → 36.29% (-22%)
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Altium Capital Management
New York
|
+$4.03M |
| 2 |
Boothbay Fund Management
New York
|
+$2.01M |
| 3 |
Great Point Partners
Greenwich,
Connecticut
|
+$1.78M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.66M |
| 5 |
BlackRock
New York
|
+$1.28M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Armistice Capital
New York
|
-$8.53M |
| 2 |
Velan Capital Investment Management
Alpharetta,
Georgia
|
-$2.03M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$355K |
| 4 |
HRT Financial
New York
|
-$341K |
| 5 |
Millennium Management
New York
|
-$331K |
OTLK Hedge Fund Activity: Q2 2024 in Review
65 of the 6,944 institutional investors tracked by Wall St. Rank reported a position in Outlook Therapeutics (OTLK) for Q2 2024, worth a combined $62.7M — down 30% from $90M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new OTLK positions and 7 closed out — a net gain of 8 holders — while 24 added to existing stakes and 12 trimmed.
The largest buyer was Altium Capital Management, opening a new position worth an estimated $4.03M. The largest seller was Armistice Capital, exiting entirely with an estimated $8.53M sold.
- 65 institutional investors held Outlook Therapeutics (OTLK) as of Q2 2024, up from 57 in Q1 2024.
- Funds reported $62.7M of Outlook Therapeutics stock for Q2 2024, down 30% quarter-over-quarter.
- 15 funds opened new Outlook Therapeutics positions in Q2 2024 and 7 closed out, a net change of +8 holders.
- The largest Outlook Therapeutics buyer in Q2 2024 was Altium Capital Management, an estimated $4.03M added.
- The largest Outlook Therapeutics seller in Q2 2024 was Armistice Capital, an estimated $8.53M sold.
Based on aggregated 13F filings for Q2 2024.